Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP1A2 | P05177 | 3/20 | 0.57 |
| ▸ | CYP3A4 | P08684 | 3/20 | 0.57 |
| ▸ | CYP2C19 | P33261 | 3/20 | 0.57 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.57 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.56 |
| ▸ | CYP2D6 | P10635 | 2/20 | 0.54 |
| ▸ | NPC1 | O15118 | 2/20 | 0.53 |
| ▸ | RAB9A | P51151 | 2/20 | 0.53 |
| ▸ | L3MBTL1 | Q9Y468 | 3/20 | 0.53 |
| ▸ | TDP1 | Q9NUW8 | 3/20 | 0.53 |
| ▸ | TSHR | P16473 | 1/20 | 0.52 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.52 |
| ▸ | HDAC1 | Q13547 | 2/20 | 0.50 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.50 |
| ▸ | HDAC3 | O15379 | 1/20 | 0.50 |
| ▸ | GAA | P10253 | 1/20 | 0.50 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.50 |
| ▸ | HTT | P42858 | 1/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6718898 | 0.79 | POLB (0.66) | SMN1; SMN2NPC1RAB9ATSHRALDH1A1 | |
| SCHEMBL8590044 | 0.76 | HDAC3 (0.47) | SMN1; SMN2NPC1RAB9AL3MBTL1HDAC1 | |
| SCHEMBL6720448 | 0.76 | NPC1 (0.73) | SMN1; SMN2NPC1RAB9AL3MBTL1TSHR | |
| SCHEMBL9868945 | 0.76 | SMN1; SMN2 (0.68) | CYP1A2CYP3A4CYP2C19CYP2C9SMN1; SMN2 | |
| SCHEMBL28316072 | 0.75 | ALDH1A1 (0.60) | CYP2C9SMN1; SMN2NPC1RAB9AHDAC1 | |
| SCHEMBL10144117 | 0.74 | THRB (0.67) | CYP1A2CYP3A4CYP2C19CYP2C9SMN1; SMN2 | |
| SCHEMBL30539453 | 0.73 | PLK1 (0.56) | SMN1; SMN2NPC1RAB9A | |
| SCHEMBL30539416 | 0.73 | HCAR2 (0.70) | CYP1A2CYP3A4CYP2C19CYP2C9SMN1; SMN2 | |
| SCHEMBL3553708 | 0.73 | L3MBTL1 (0.56) | CYP1A2CYP3A4CYP2C19CYP2C9SMN1; SMN2 | |
| SCHEMBL8369690 | 0.73 | TSHR (0.49) | L3MBTL1TDP1TSHRMAPK1ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20040087491-A1 | Electrophilic ketones for the treatment of herpesvirus infections | FLYNN DANIEL L (US) | 2004-05-06 | — | — | US | claimed |
| US-20040087491-A1 | Electrophilic ketones for the treatment of herpesvirus infections | FLYNN DANIEL L (US) | 2004-05-06 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040087491-A1 | Electrophilic ketones for the treatment of herpesvirus infections | KHK, HCK, PBK | CYP1A2 290/4885CYP3A4 242/4885CYP2C19 790/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.